Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
February 21, 2021
It Will Take The G-7 To Stop Covid-19: Here Are 5 Reasons Why
January 28, 2021
Bellicum Pharmaceuticals (BLCM) FDA has lifted the clinical hold
January 26, 2021
Precigen (PGEN) closes 17.25 M share offering at $7.50
January 19, 2021
Editas Medicine (EDIT) proposes 3.5 million shares offering
January 12, 2021
REGENXBIO (RGNX) closes 4.26 million share offering at $47.00
December 11, 2020
Solid Biosciences (SLDB) executes a $90 M Private Placement
December 10, 2020
RegMed/Cell and Gene Therapy Earnings Scorecard Q3/20 LPS Results
November 4, 2020
Bellicum Pharmaceuticals (BLCM) closes 1.04 M share offering
September 15, 2020
Q2/20 Earnings - (LPS - loss-per-share) Results
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors